Respironics grows sleep disorder business with Apollo buy:
This article was originally published in Clinica
Executive Summary
Sleep and respiratory treatment specialist Respironics has expanded its reach in the sleep disorder therapy market with the purchase of Apollo Light Systems for $6.5m. Murrysville, Pennsylvania-based Respironics, which is looking to broaden its scope beyond its core business of treating obstructive sleep apnea, will add Apollo's light therapy systems for melatonin suppression and circadian rhythm sleep disorders to its Sleep Well Ventures business. The deal will see additional payments made by Respironics to Apollo based on the latter's operating performance over the next year. Apollo (American Fork, Utah) generates annual revenues of around $5m from sales of its briteLITE and goLITE light therapy systems and its Daybreak Sunrise simulators.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.